Clinical trial
Study of Ro 205-2349 in Patients With Type 2 Diabetes Mellitus
NCT00057317 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00057317 |
|---|---|
| Title | Study of Ro 205-2349 in Patients With Type 2 Diabetes Mellitus |
| Official title | A Phase II, Randomized, Double-blind, Placebo-controlled Dose-ranging Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of Ro 205-2349 in Patients With Type 2 Diabetes Mellitus |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Diabetes |
| Intervention type | Drug |
| Interventions | Ro 205-2349 |
| Start date | Dec 1, 2001 |
| Primary completion | Dec 1, 2003 |
| Completion | Dec 1, 2003 |
| First posted | Apr 1, 2003 |
| Last update posted | Aug 24, 2016 |
| Countries | Bulgaria, Canada, Estonia, Latvia, Lithuania, Mexico, Panama, Puerto Rico, Romania, United Kingdom, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: